Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

MYSTERY weight-loss drugs are being sold illegally at “skinny jab parties” – with one dealer claiming she buys meds in powder ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Weight loss can reverse the cardiovascular changes that take place in the heart, but will a new diet and exercise work, or is ...